Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia

Clinical Neurophysiology

Volumn 124, Issue 11, 2013, Pages 2209-2215

  Ballesteros, Alejandro ^a,b   Summerfelt, Ann ^a   Du, Xiaoming ^a   Jiang, Pan ^a   Chiappelli, Joshua ^a   Tagamets, Malle ^a   O'Donnell, Patricio ^a   Kochunov, Peter ^a   Hong, L Elliot ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

GSH; GSSG; MMN; Oscillations; Oxidation; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MEDIATOR; MISMATCH NEGATIVITY; OSCILLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

EID: 84885861347     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2013.05.021     Document Type: Article

References (62)

1. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
2. Ben Othmen L., Mechri A., Fendri C., Bost M., Chazot G., Gaha L., et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:155-159.
3. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008, 64:361-368.
4. Bramon E., Croft R.J., McDonald C., Virdi G.K., Gruzelier J.G., Baldeweg T., et al. Mismatch negativity in schizophrenia: a family study. Schizophr Res 2004, 67:1-10.
5. Cabungcal J.H., Steullet P., Kraftsik R., Cuenod M., Do K.Q. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry 2013, 73:574-582.
6. Carlen M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 2012, 17:537-548.
7. Carmeli C., Knyazeva M.G., Cuenod M., Do K.Q. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS ONE 2012, 7:e29341.
8. Cho R.Y., Konecky R.O., Carter C.S. Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 2006, 103:19878-19883.
9. Choi Y.B., Lipton S.A. Redox modulation of the NMDA receptor. Cell Mol Life Sci 2000, 57:1535-1541.
10. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
11. Do K.Q., Trabesinger A.H., Kirsten-Kruger M., Lauer C.J., Dydak U., Hell D., et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
12. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009, 19:220-230.
13. Gandal M.J., Sisti J., Klook K., Ortinski P.I., Leitman V., Liang Y., et al. GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2012, 2:e142.
14. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Yatham L.N., Young L.T. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011, 14:1069-1074.
15. Green M.F., Schooler N.R., Kern R.S., Frese F.J., Granberry W., Harvey P.D., et al. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 2011, 168:400-407.
16. Griffith O.W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980, 106:207-212.
17. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull 2012, 38:950-957.
18. Guntherberg H., Rost J. The true oxidized glutathione content of red blood cells obtained by new enzymic and paper chromatographic methods. Anal Biochem 1966, 15:205-210.
19. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007, 104:16621-16626.
20. Hall M.H., Schulze K., Rijsdijk F., Picchioni M., Ettinger U., Bramon E., et al. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav Genet 2006, 36:845-857.
21. Harvey P.D., Velligan D.I., Bellack A.S. Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr Bull 2007, 33:1138-1148.
22. Hassler U., Barreto N.T., Gruber T. Induced gamma band responses in human EEG after the control of miniature saccadic artifacts. NeuroImage 2011, 57:1411-1421.
23. Hayes AF. PROCESS: A versatile computational tool for observed variable mediation, moderation, and conditional process modeling. White Paper. 2012. Retrieved from http://www.afhayes.com/public/process2012.pdf.
24. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27:11496-11500.
25. Hong L.E., Summerfelt A., Mitchell B.D., McMahon R.P., Wonodi I., Buchanan R.W., et al. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008, 65:1008-1016.
26. Hong L.E., Summerfelt A., Buchanan R.W., O'Donnell P., Thaker G.K., Weiler M.A., et al. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2010, 35:632-640.
27. Iwasaki Y., Saito Y., Nakano Y., Mochizuki K., Sakata O., Ito R., et al. Chromatographic and mass spectrometric analysis of glutathione in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:3309-3317.
28. Kohr G., Eckardt S., Luddens H., Monyer H., Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994, 12:1031-1040.
29. Javitt D.C., Doneshka P., Zylberman I., Ritter W., Vaughan H.G. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry 1993, 33:513-519.
30. Javitt D.C., Doneshka P., Grochowski S., Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 1995, 52:550-558.
31. Javitt D.C., Steinschneider M., Schroeder C.E., Arezzo J.C. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci USA 1996, 93:11962-11967.
32. Javitt D.C., Grochowski S., Shelley A.M., Ritter W. Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalogr Clin Neurophysiol 1998, 108:143-153.
33. Javitt D.C., Shelley A., Ritter W. Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin Neurophysiol 2000, 111:1733-1737.
34. Javitt D.C., Schoepp D., Kalivas P.W., Volkow N.D., Zarate C., Merchant K. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011, 3:102mr2.
35. Kulak A., Cuenod M., Do K.Q. Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder. Behav Brain Res 2012, 226:563-570.
36. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175.
37. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
38. Light G.A., Hsu J.L., Hsieh M.H., Meyer-Gomes K., Sprock J., Swerdlow N.R., et al. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry 2006, 60:1231-1240.
39. Magno E., Yeap S., Thakore J.H., Garavan H., De Sanctis P., Foxe J.J. Are auditory-evoked frequency and duration mismatch negativity deficits endophenotypic for schizophrenia? High-density electrical mapping in clinically unaffected first-degree relatives and first-episode and chronic schizophrenia. Biol Psychiatry 2008, 64:385-391.
40. Miljevic C., Nikolic M., Nikolic-Kokic A., Jones D.R., Niketic V., Lecic-Tosevski D., et al. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:303-307.
41. Nakazawa K., Zsiros V., Jiang Z., Nakao K., Kolata S., Zhang S., et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
42. Nicol R.M., Chapman S.C., Vertes P.E., Nathan P.J., Smith M.L., Shtyrov Y., et al. Fast reconfiguration of high-frequency brain networks in response to surprising changes in auditory input. J Neurophysiol 2012, 107:1421-1430.
43. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr Bull 2011, 37:484-492.
44. O'Donnell P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci 2012, 35:1866-1870.
45. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 2001, 27:235-245.
46. Preacher K.J., Hayes A.F. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput 2004, 36:717-731.
47. Preacher K.J., Kelley K. Effect size measures for mediation models: quantitative strategies for communicating indirect effects. Psychol Methods 2011, 16:93-115.
48. Raffa M., Atig F., Mhalla A., Kerkeni A., Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011, 11:124.
49. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122.
50. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 1991, 30:1059-1062.
51. Sohal V.S., Zhang F., Yizhar O., Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009, 459:698-702.
52. Spencer K.M., Nestor P.G., Perlmutter R., Niznikiewicz M.A., Klump M.C., Frumin M., et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci USA 2004, 101:17288-17293.
53. Steullet P., Cabungcal J.H., Kulak A., Kraftsik R., Chen Y., Dalton T.P., et al. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. J Neurosci 2010, 30:2547-2558.
54. Sullivan E.M., O'Donnell P. Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr Bull 2012, 38:373-376.
55. Twamley E.W., Doshi R.R., Nayak G.V., Palmer B.W., Golshan S., Heaton R.K., et al. Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry 2002, 159:2013-2020.
56. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci 2010, 11:100-113.
57. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005, 76:1-23.
58. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000, 57:1139-1147.
59. Umbricht D.S., Bates J.A., Lieberman J.A., Kane J.M., Javitt D.C. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol Psychiatry 2006, 59:762-772.
60. Welch P.D. The use of fast fourier transform for estimation of power spectra: a method based on time averaging over short, modified periodograms. IEEE Trans Audio Electroacoust 1967, AU-15:70-73.
61. Wood S.J., Berger G.E., Wellard R.M., Proffitt T.M., McConchie M., Berk M., et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis 2009, 33:354-357.
62. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.